Loading
An trial of Rocapuldencel-T run by Mayo Clinic, withdrawn before enrolling.
Gemcitabine Hydrochloride, Cisplatin, and AGS-003-BLD in Treating Patients With Muscle-Invasive Bladder Cancer Undergoing Surgery is an interventional study registered as NCT02944357 by Mayo Clinic, started 2016-11. Conditions recorded: Infiltrating Bladder Urothelial Carcinoma, Stage II Bladder Urothelial Carcinoma, Stage III Bladder Urothelial Carcinoma and Stage IV Bladder Urothelial Carcinoma. Interventions recorded: Cisplatin, Gemcitabine Hydrochloride, Radical Cystectomy and Tumor Cell-Derived Vaccine Therapy.
Shares Rocapuldencel-T, Argos Therapeutics and the tag pipeline.
Shares Rocapuldencel-T, Argos Therapeutics and the tag pipeline.
Shares Rocapuldencel-T, Argos Therapeutics and the tag pipeline.
Shares Rocapuldencel-T, Argos Therapeutics and the tag pipeline.
Shares Rocapuldencel-T, Argos Therapeutics and the tag pipeline.
Shares Rocapuldencel-T, Argos Therapeutics and the tag pipeline.
Shares Bladder & urothelial cancer and the tag pipeline.
Shares Bladder & urothelial cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/